EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Treatment‐Free Remission in Chronic Myeloid Leukemia: Revisiting the “W” Questions

Antonella Bruzzese iD, Ernesto Vigna, Enrica Antonia Martino, Nicola Amodio, Caterina Labanca, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Fortunato Morabito iD, Massimo Gentile

European Journal of Haematology · 2025

DOI: 10.1111/ejh.70000 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Antonella Bruzzese und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Protein Kinase Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic myeloid leukemia (CML) has undergone a transformation from a fatal disease to a chronic, manageable condition with the advent of tyrosine kinase inhibitors (TKIs), particularly imatinib. This shift has significantly improved survival rates, and for some patients, achieving deep molecular response (DMR) has made treatment‐free remission (TFR) a feasible goal. However, the ability to sustain TFR remains a challenge, primarily due to the persistence of leukemia stem cells (LSCs), which are inherently resistant to TKIs and contribute to relapse after treatment cessation. The barriers to TFR include not only the persistence of LSCs but also the complex biology of resistance mechanisms. Attempts to overcome these barriers through TKI rotation, second‐generation TKIs, or strategies targeting the tumor microenvironment have shown limited success. Third‐generation TKIs like ponatinib and novel agents such as asciminib and olverembatinib offer promising therapeutic alternatives, particularly for patients with the T315I mutation. However, their use is constrained by safety concerns and limited availability, especially in low‐resource settings. Patient selection remains a crucial aspect of achieving TFR, as not all patients with DMR sustain remission after discontinuation of therapy. Factors such as age, immune profile, and measurable residual disease levels significantly influence relapse risk. Identifying reliable clinical and molecular predictors of successful TFR is essential for optimizing treatment strategies and improving outcomes. The concept of the “W” questions—who, when, why, what, and where—frames the future of TFR in CML. Who should be selected for TFR? When should TFR be pursued? Why are some patients successful in achieving and sustaining TFR, while others relapse? What strategies can enhance the likelihood of TFR success, such as novel therapies, combination treatments, and patient‐specific approaches? Where should these strategies be implemented to ensure equitable access, particularly in resource‐limited settings? This review highlights the progress made in CML treatment, emphasizes the need for precision medicine to personalize TFR strategies, and stresses the importance of answering the fundamental “W” questions to advance the field. Future research must focus on refining predictive models, exploring new therapeutic options, and expanding access to treatments to ensure equitable benefits for all CML patients globally.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsHumansRemission InductionDrug Resistance, NeoplasmFusion Proteins, bcr-ablAntineoplastic AgentsTreatment OutcomeNeoplastic Stem CellsMolecular Targeted TherapyDisease ManagementMutation

Stichwörter der Autor:innen

CMLTFRTKI

Substanzen

Protein Kinase InhibitorsFusion Proteins, bcr-ablAntineoplastic Agents

Autor:innen und Institutionen

  • Hematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy.
  • Department of Experimental and Clinical Medicine, University of Catanzaro, Catanzaro, Italy.
  • AIL Sezione di Cosenza, Cosenza, Italy.
  • Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy.

ORCID-Profile: Antonella Bruzzese, Fortunato Morabito

Zitieren

APA

Bruzzese, A., Vigna, E., Martino, E. A., Amodio, N., Labanca, C., Mendicino, F., Lucia, E., Olivito, V., Morabito, F., & Gentile, M. (2025). Treatment‐Free Remission in Chronic Myeloid Leukemia: Revisiting the “W” Questions. European Journal of Haematology. https://doi.org/10.1111/ejh.70000

Vancouver

Bruzzese A, Vigna E, Martino EA, Amodio N, Labanca C, Mendicino F, et al. Treatment‐Free Remission in Chronic Myeloid Leukemia: Revisiting the “W” Questions. European Journal of Haematology. 2025. doi:10.1111/ejh.70000

BibTeX
@article{Bruzzese2025,
  author = {Bruzzese, Antonella and Vigna, Ernesto and Martino, Enrica Antonia and Amodio, Nicola and Labanca, Caterina and Mendicino, Francesco and Lucia, Eugenio and Olivito, Virginia and Morabito, Fortunato and Gentile, Massimo},
  title = {Treatment‐Free Remission in Chronic Myeloid Leukemia: Revisiting the “W” Questions},
  journal = {European Journal of Haematology},
  year = {2025},
  doi = {10.1111/ejh.70000}
}
Kostenlos starten →